Kura Oncology
Updated: January 11, 2026
CEO Troy Wilson
Country: USA | Funding: $1.2B (+)
Founded: 2014
Website: https://www.kuraoncology.com/
Kura Oncology develops precision small-molecule drugs for treatment of solid tumors and blood cancers. The company discovers and tests new biomarkers of cancer signaling pathways. Kura's flagship drug, COMZIFTI, is approved for the treatment of adult patients with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) gene mutation whose AML has relapsed or failed to improve after previous treatment and who have no other satisfactory treatment options. The company's pipeline also includes clinical trials for acute lymphoblastic leukemia, acute myeloid leukemia, advanced gastrointestinal stromal tumors, renal cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and head and neck squamous cell carcinoma.
Founded: 2014
Website: https://www.kuraoncology.com/
Kura Oncology develops precision small-molecule drugs for treatment of solid tumors and blood cancers. The company discovers and tests new biomarkers of cancer signaling pathways. Kura's flagship drug, COMZIFTI, is approved for the treatment of adult patients with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) gene mutation whose AML has relapsed or failed to improve after previous treatment and who have no other satisfactory treatment options. The company's pipeline also includes clinical trials for acute lymphoblastic leukemia, acute myeloid leukemia, advanced gastrointestinal stromal tumors, renal cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and head and neck squamous cell carcinoma.
